WaveMan
WaveMan · Company
LBRX · Lb Pharmaceuticals Inc
> Search tickers & screens ⌘K
LIVE
← All companies

LBRX LB Pharmaceuticals (LBRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001691082
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
84
13F, latest reported quarter

LB Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for LB PHARMACEUTICALS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Deep Track Capital, LP
BUY
2025-09-16 SECtraded 2025-09-12
2,000,000
$30.0M
+137.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 74.5% of the 2,686,138 shares held after it.
  • 3 other insiders bought within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Deep Track Capital, LP bought about $30.0M of LBRX on Sep 12, 2025, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 84 funds added in the latest 13F quarter.
Deep Track Capital, LP
BUY
2025-09-16 SECtraded 2025-09-12
666,666
$10.0M
+137.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 666,666 shares held after it.
  • 3 other insiders bought within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Deep Track Capital, LP bought about $10.0M of LBRX on Sep 12, 2025, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 84 funds added in the latest 13F quarter.
Pontifax Management 4 G.P. (2015) Ltd.
BUY
2025-09-16 SECtraded 2025-09-12
1,000,000
$15.0M
+137.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 70.8% of the 1,411,681 shares held after it.
  • 3 other insiders bought within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Pontifax Management 4 G.P. (2015) Ltd. bought about $15.0M of LBRX on Sep 12, 2025, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 84 funds added in the latest 13F quarter.
Nussbaum Ran
Director
BUY
2025-09-16 SECtraded 2025-09-12
1,000,000
$15.0M
+137.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 70.8% of the 1,411,681 shares held after it.
  • 3 other insiders bought within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Nussbaum Ran bought about $15.0M of LBRX on Sep 12, 2025, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 84 funds added in the latest 13F quarter.
Vida Ventures GP III, L.L.C.
BUY
2025-09-16 SECtraded 2025-09-12
332,566
$5.0M
+137.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 37.8% of the 880,214 shares held after it.
  • 3 other insiders bought within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Vida Ventures GP III, L.L.C. bought about $5.0M of LBRX on Sep 12, 2025, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 84 funds added in the latest 13F quarter.
6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 1 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
84 funds bought in last quarter
more than 62% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
22.7% of the float short (float per yahoo 2026-10-26) · 14.5 days to cover · settled 2026-09-30
more than 92% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LBRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+146.5%12M
-7%+67%+141%+215%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LBRX: institutional holders (13F)

13F holdings, latest reported quarter
Deep Track Capital, LP
3,352,804 sh
$108.8M
BlackRock, Inc.
2,734,305 sh
$88.7M
RA CAPITAL MANAGEMENT, L.P.
2,208,604 sh
$71.7M
Nantahala Capital Management, LLC
2,105,788 sh
$68.3M
Trails Edge Capital Partners, LP
1,523,022 sh
$49.4M

Congress trades in LBRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LBRX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

LBRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$438.3K position · as of 2026-07-31
0.9%
JPMorgan Small Cap Growth Fund
$22.5M position · as of 2026-06-30
0.9%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$3.4M position · as of 2026-06-30
0.8%
PROFUND VP PHARMACEUTICALS
$89.0K position · as of 2026-06-30
0.8%
Calamos Timpani Small Cap Growth Fund
$5.8M position · as of 2026-07-31
0.8%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$151.5K position · as of 2026-07-31
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
1 active
2
Phase 3
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 84 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LBRX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$82.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-75.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-23.7%
TTM net income over ending balance 2026-06-30
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
276.64x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
-6.6%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Net income-$25.2M-$63.1M
EPS (diluted)-3.13-176.15
Operating cash flow-$35.2M-$53.1M
Cash$250.2M$23.0M
SEC XBRL, fiscal years, as known on 2026-10-27

LBRX Stock Sonar score 3/7 axes

Find similar shapesCompare

LBRX ranks highest on institutional and government (62nd percentile) and profitability (53rd), and lowest on risk and compliance (11th), among Pharma & Biotech peers.

Profitability
53
Inputs
  • Return on equity-75.0% · 41 pct, sector of 545
  • Return on assets-23.7% · 64 pct, sector of 691
  • Return on invested capitalfewer than four consecutive quarters of operating income
  • Return on capital employedfewer than four consecutive quarters of operating income
Institutional and government
62
Inputs
  • Funds adding, latest quarter84 · 62 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
11
Inputs
  • Short interest, % of float+22.7% · 11 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies